Monthly Archives: June 2017


Mitochondria behind blood cell formation – Phys.org – Phys.Org

June 13, 2017 Mitochondria are tiny, free-floating organelles inside cells. New Northwestern Medicine research has discovered that they play an important role in hematopoiesis, the bodys process for creating new blood cells. Credit: Northwestern University

New Northwestern Medicine research published in Nature Cell Biology has shown that mitochondria, traditionally known for their role creating energy in cells, also play an important role in hematopoiesis, the body's process for creating new blood cells.

"Historically, mitochondria are viewed as ATPenergyproducing organelles," explained principal investigator Navdeep Chandel, PhD, the David W. Cugell Professor of Medicine in the Division of Pulmonary and Critical Care Medicine. "Previously, my laboratory provided evidence that mitochondria can dictate cell function or fate independent of ATP production. We established the idea that mitochondria are signaling organelles."

In the current study, Chandel's team, including post-doctoral fellow Elena Ans, PhD, and graduate students Sam Weinberg and Lauren Diebold, demonstrated that mitochondria control hematopoietic stem cell fate by preventing the generation of a metabolite called 2-hydroxyglutarate (2HG). The scientists showed that mice with stem cells deficient in mitochondrial function cannot generate blood cells due to elevated levels of 2HG, which causes histone and DNA hyper-methylation.

"This is a great example of two laboratories complementing their expertise to work on a project," said Chandel, also a professor of Cell and Molecular Biology and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Paul Schumacker, PhD, professor of Pediatrics, Cell and Molecular Biology and Medicine, was also a co-author on the paper.

Chandel co-authored an accompanying paper in Nature Cell Biology, led by Jian Xu, PhD, at the University of Texas Southwestern Medical Center, which demonstrated that initiation of erythropoiesis, the production of red blood cells specifically, requires functional mitochondria.

"These two studies collectively support the idea that metabolism dictates stem cell fate, which is a rapidly evolving subject matter," said Chandel, who recently wrote a review in Nature Cell Biology highlighting this idea. "An important implication of this work is that diseases linked to mitochondrial dysfunction like neurodegeneration or normal aging process might be due to elevation in metabolites like 2HG."

Explore further: Novel method enables absolute quantification of mitochondrial metabolites

More information: Elena Ans? et al. The mitochondrial respiratory chain is essential for haematopoietic stem cell function, Nature Cell Biology (2017). DOI: 10.1038/ncb3529

Whitehead Institute scientists have developed a method to quickly isolate and systematically measure metabolite concentrations within the cellular organelles known as mitochondria, often referred to as the "powerhouses of ...

A new University of Colorado Boulder study shows for the first time the final stages of how mitochondria, the sausage-shaped, power-generating organelles found in nearly all living cells, regularly divide and propagate.

Using yeast cells as a model, scientists from the A.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University investigated the mechanisms that allow cells to protect themselves from invasion of ...

Researchers at NYU Langone Medical Center have discovered that mitochondria, the major energy source for most cells, also play an important role in stem cell developmenta purpose notably distinct from the tiny organelle's ...

Aging, neurodegenerative disorders and metabolic disease are all linked to mitochondria, structures within our cells that generate chemical energy and maintain their own DNA. In a fundamental discovery with far-reaching implications, ...

Researchers at UT Southwestern Medical Center have uncovered the mechanism that cells use to find and destroy an organelle called mitochondria that, when damaged, may lead to genetic problems, cancer, neurodegenerative diseases, ...

There are many ways to make a living in a suitable climate but far fewer in a less suitable one. That may seem obvious for people living under various socio-economic stresses, but new research shows it also applies to the ...

Adult females and males in a newly identified genus of Latin American praying mantises have evolved sharply different camouflage strategies, according to a Cleveland Museum of Natural History-led study published in the journal ...

Male birds tend to be better singers than femalesbut does the basis for this difference lie in the brain or in the syrinx, the bird equivalent of our larynx? The researchers behind a new study from The Auk: Ornithological ...

Animals living in areas where conditions are ideal for their species have less chance of evolving to cope with climate change, new research suggests.

The arrangement of the photoreceptors in our eyes allows us to detect socially significant color variation better than other types of color vision, a team of researchers has found. Specifically, our color vision is superior ...

Using high magnification imaging, a team of researchers has identified several never before seen structures on bacteria that represent molecular machinery. The research is published this week in the Journal of Bacteriology, ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to read the rest:
Mitochondria behind blood cell formation - Phys.org - Phys.Org

Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic … – The Scientist

Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic ...
The Scientist
Cambridge, UK, 14 June 2017: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the Company), the world leader in the application of gene editing technologies, today announces progress of its gene and cell therapy platform for contract service and ...

and more »

Link:
Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic ... - The Scientist

Global Autologous Cell Therapy Market – Analysis, Technologies & Forecasts to 2021 – Increasing Demand for Effective … – Business Wire (press…

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Autologous Cell Therapy Market 2017-2021" report to their offering.

The global autologous cell therapy market to grow at a CAGR of 23.39% during the period 2017-2021.

The report, Global Autologous Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

The latest trend gaining momentum in the market is private funding will fuel market growth. The increasing investments from private enterprises will likely change the market dynamics. Many vendors are investing in production or manufacturing facilities to improve their production or manufacturing expertise. They are also focusing on establishing new business units or companies to penetrate the market further.

According to the report, one of the major drivers for this market is increasing demand for effective drugs for cardiac and degenerative disorders. There has been an increased demand for providing effective drugs for cardiac and degenerative disorders globally. Prior to the advent of autologous cell therapies, there was no effective drug to repair a damaged heart. The discovery of possible cardiac autologous cells opened new possibilities for repairing damaged cardiac tissue caused by acute myocardial infarction or coronary artery disease.

Key vendors

Other prominent vendors

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Pipeline Landscape

PART 06: Market landscape

PART 07: Market segmentation by application

PART 08: Market Segmentation by therapy

PART 09: Geographical segmentation

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

For more information about this report visit http://www.researchandmarkets.com/research/633cdq/global_autologous

Visit link:
Global Autologous Cell Therapy Market - Analysis, Technologies & Forecasts to 2021 - Increasing Demand for Effective ... - Business Wire (press...

Former Kilkenny star Richie Power hoping stem-cell therapy can fix … – The Irish Sun

Power was forced to retire from inter-county hurling with the injury two years ago at the age of 29

RICHIE POWER hopes radical new stem-cell therapy in Croatia can fix his battered knee.

The eight-time All-Ireland medallist with Kilkenny retired in the wake of the 2015 Liam MacCarthy triumph at the age of just 29.

Power had three operations on his left knee that year alone and admits rushing back too soon ultimately ended his career.

The speedy attacker got back to Croke Park in February with AIB All-Ireland intermediate club champions Carrickshock.

But he has not played for them since and his quality of life has suffered with his knee causing him constant pain.

Ex-Kilkenny hurler David Byrne, who works with an American company linked to a hospital in Zagreb, put Power on the stem-cell trail.

Power said: The process is about regenerating cartilage in the left knee.

They take some good cartilage from the right knee, bring it into the lab and more or less clone it.

Then they inject it back into your left knee and you are hoping then that the blood will run to it and regenerate there.

From what I gather, youre not looking at a huge period of time out.

You have two or three months to help it and they bring you back over every three months for a check-up to see if its working.

The big issue is that I dont think theres anyone who has stood over it and said, Yeah, it definitely works, because they are waiting to see five, ten, 15 years down the line as to how it helps.

The feedback has been positive. Its worth a try.

The former Cats star is not looking to revive his county career though even if Kilkenny could do with him.

He is simply looking for a better quality of life and to extend his club career by a few more years.

Power added: If I dont get anything done in Croatia and if I decide to go back playing for another year or two and keep struggling through, then Im probably looking at a knee replacement by the time Im 40.

Im only 31 so its not something I want to face at such a young age.

It is just to try to give me an extra 15 or 20 years with my own knee.

If they can do that then great, it will be well worth it. If not, then I need to make a decision and maybe hang up the boots altogether.

More here:
Former Kilkenny star Richie Power hoping stem-cell therapy can fix ... - The Irish Sun

Kilkenny legend Richie Power: ‘Stem-cell treatment is my last hurrah … – Independent.ie

Following extensive research the eight-time All-Ireland winner has opted to take a leaf out of the book of many American Football players and hopes such therapy can help prolong an inevitable knee replacement.

To keep hurling with Carrickshock would be a bonus but doing the simple things in life without pain is what really attracted him to Zagreb clinic (which costs "under 1,000") in what he admits is "a last hurrah" after six operations.

"It's regenerating the cartilage in the left knee. They take some good cartilage from the right knee, bring it into the lab and more or less clone it.

"Then they inject it back into your left knee and you are hoping that the blood will run to it and regenerate there," the 31-year-old former Kilkenny star said.

"It's not to get back playing. It's just to get a quality of life with my own knee. Some days I'd find it hard to go and puck around with Rory (his son) like.

"That makes it very hard. It's for things like that as the years go on. I'm probably looking at a knee replacement by the time I'm 40.

"It is just to try and give me an extra 15-20 years with my own knee and if they can do that then great, it will be well worth it. If not I need to make a decision and maybe end up hanging up the boots altogether. Look, if it has to be done it has to be done.

"I'd like to be in a position where I am completely pain-free. I'd like to maybe run around and not worry about the leg going under me. I went to see everyone. I sat down with the Aussie Rules doctors and teams when they were here and absolutely everyone and anyone that I could. This is the last hurrah. If it doesn't work, it doesn't work."

Subscribe to The Throw-In, Independent.ie's weekly Championship podcast, for the best in GAA discussion and analysis every Monday, with some of the biggest names in football and hurling from Joe Brolly, Toms 'S, Brendan Cummins and John Mullane.

See more here:
Kilkenny legend Richie Power: 'Stem-cell treatment is my last hurrah ... - Independent.ie

Hong Kong biotech start-up claims world first in stem cell treatment of Alzheimer’s and Parkinson’s diseases – South China Morning Post

Oper Technology, a Hong Kong biotechnology start-up, has pioneered what it claims is a world first in stem cell treatment that it says could potentially help millions of patients suffering from Alzheimers and Parkinsons diseases.

The business was co-founded by Hong Kong Baptist Universitys Professor Ken Yung, who specialises in neurobiology and neurological diseases in the universitys biology department.

He and his team has now developed a method of harvesting neural stem cells from the brains of live subjects using specially developed nanoparticles.

The exploration of using stem cells to repair damaged neural cells is not a new concept. Scientists in the US and elsewhere have experimented using stem cells from fat and skin, developing them into neural cells.

But Yung claims his team is the first to successfully harvest stem cells directly from the brain and re-inject the developed neural cells back into a live subject, thereby artificially regenerating any cells which have died off, due to neurological diseases from neural stem cells themselves.

Stem cells have the potential to develop into different types of cells with specialised functions.

The nanoparticles which are made of a type of iron oxide work like magnets to attract the stem cells within the brain.

Yung said these can then be developed into more specific neural cells and re-injected into the brain to replace damaged cells caused by diseases such as Alzheimers and Parkinsons, where neurons in the patients brains progressively die off with time.

He suggests the treatment could benefit almost 100 million patients around the world, who suffer from neurodegenerative diseases, including strokes.

China alone has the largest population of people with dementia, with an estimated 23.3 million now projected to suffer from the condition by 2030, according to the World Health Organisation.

Yung co-founded Oper Technology and serves as its chairman.

The company is being developed under Hong Kong Science and Technology Parks Incu-Bio programme, which provides select biotechnology start-ups with laboratory and support services, and ultimately it aims to commercialise its medical technology.

If you put the [developed] cells in a different environment from where the [stem cells are harvested], there might be [misdirected] growth in an uncontrolled environment, said Yung.

We want to use neural cells to repair neural cells, and since the stem cells and re-injected neural cells are from the same micro-environment, there will not be uncontrollable growth.

The method has proven to be very successful when tested on rats, especially in cases of Parkinsons, according to Yung, who suggested the method could eventually become an ultimate treatment for the disease.

Furthermore, the risks of this treatment are similar to what is currently on the market today, he added.

The treatment could also help to treat early-stage Alzheimers patients, slowing down or even halting the degeneration process, although Yung acknowledged that its effectiveness in treating terminal stage patients may be limited since it would be difficult to regenerate enough neural cells when patients brains have shrunk due to the condition.

While animals subjected to the treatment displayed an improvement in neural function following the re-injection, the team has yet to start on clinical trials as such cell therapy is still nascent and largely unregulated in Hong Kong.

Oper Technology is currently seeking investment and often sets up booths at conferences such as last weeks EmTech Hong Kong conference, which focuses on innovation and emerging technologies.

Yung hopes to raise enough funds to begin clinical trials in Australia in the near future, where autologous cell therapies are legal and thus provides an ideal environment for clinical trials.

Read the original here:
Hong Kong biotech start-up claims world first in stem cell treatment of Alzheimer's and Parkinson's diseases - South China Morning Post

Stem Cell Therapy Becomes Law in Texas – PR Newswire (press release)

"At StemGenex, we are committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells," said Alexander. "Specifically, we use adipose-derived adult stem cell therapy for patients battling conditions such as Multiple Sclerosis, Parkinson's disease, COPD, Rheumatoid Arthritis and Osteoarthritis. We are also committed to the science of stem cell therapy and sponsor five clinical outcome studiesregistered with theNational Institute of Health (NIH) for these diseases."

"What I personally witnessed before the start of StemGenex were patients who had exhausted conventional medical treatments but wanted to try alternative therapies. I was one of them, suffering from severe Rheumatoid Arthritis. Ihad only three options; I could seek a clinical trial, travel to outside of the U.S. to try alternative therapies such as stem cell treatment or petition the FDA for access to drugs under the agency's "expanded access," or "compassionate use" program. Now, new state laws like the one just passed in Texas, built on model legislation from the Goldwater Institute in Arizona, will allow doctors and patients to make their own informed decisions on treatments that have cleared the safety phase of FDA testing."

Last year, in a move that was seen by some as a response to "Right to Try" laws, the 21st Century Cures Act, a landmark piece of legislation focused on medical innovation and medical research, was signed into law by President Obama. This Act provides the FDA with the flexibility to accelerate how it evaluates regenerative medicine treatments, such as stem cell therapies, while maintaining its high standards of safety and efficacy.

"We're on the cusp of a major change on how patients can access stem cell therapy," saidAlexander. "Today, new treatments and advances in research are giving new hope to people affected by a wide range of autoimmune and degenerative illnesses," said Alexander. "StemGenex Medical Group is proud to offer the highest quality of care and to potentially help those with unmet clinical needs improve their quality of life."

ABOUT StemGenex Medical Group

StemGenex Medical Group is committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex provides stem cell therapy options for individuals suffering with inflammatory and degenerative illnesses. Committed to the science and innovation of stem cell treatment,StemGenex sponsors five clinical outcome studiesregistered with theNational Institutes of Health (NIH) for Multiple Sclerosis, Parkinson's Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (COPD) and Osteoarthritis. These have been established to formally document and evaluate the quality of life changes in individuals following adipose-derived stem cell treatment.

Contact: Jamie Schubert, Director of Media & Community Relations jschubert@StemGenex.com, (858) 242-4243

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stem-cell-therapy-becomes-law-in-texas-300472809.html

SOURCE StemGenex Medical Group

http://www.stemgenex.com

Read more here:
Stem Cell Therapy Becomes Law in Texas - PR Newswire (press release)

Stem cell research program out of funds in three years – San Diego Reader

Californias taxpayer-funded $3 billion stem cell research program, officially known as the California Institute for Regenerative Medicine, is spending money at the rate of $22,000 an hour, and expected to run out of cash in three years, reports Capitol Weekly.

The multi-billion-dollar bond borrowing was authorized by state voters in 2004 after elite scientists and Hollywood stars, including Parkinsons sufferer Michael J. Fox and quadriplegic Christopher Reeve, argued in a $34 million ballot campaign that medical miracles were just around the corner. They teased the public, Jim Lott, an ex-vice president of the Hospital Association of Southern California and critic of the program told Capitol Weekly. They teased us with Proposition 71. And they did not deliver on the tease, and I dont want them to be able to get away with that again.

Additional funding sought by the institute, critics say, should be conditioned on reforming the way cash grants are handed out, which currently go overwhelmingly to those affiliated with institutions who control seats on the stem cell groups board. We need to do this in a more responsible and accountable way, according to Lott.

As the battle for new money ramps up, UCSDs Sanford Stem Cell Clinical Center, number four among top funding recipients, is looking for a new communications director, to receive a salary commensurate with experience. Says an online job notice, This position works closely with and supports the Executive Director on communications of scientific and medical information of interest to our community and constituents.

Minimum qualifications include demonstrated experience in writing and editing promotional materials, e.g. newsletters, brochures, web announcements, fact sheets, background pieces, etc. Another requirement: Must be willing to work on projects where animals and human embryonic stem cells are used in research.

View post:
Stem cell research program out of funds in three years - San Diego Reader

Brain Cell Transplants Are Being Tested Once Again For Parkinson’s – NPR

Researchers are working to revive a radical treatment for Parkinson's disease.

The treatment involves transplanting healthy brain cells to replace cells killed off by the disease. It's an approach that was tried decades ago and then set aside after disappointing results.

Now, groups in Europe, the U.S. and Asia are preparing to try again, using cells they believe are safer and more effective.

"There have been massive advances," says Claire Henchcliffe, a neurologist at Weill Cornell Medicine in New York. "I'm optimistic."

"We are very optimistic about ability of [the new] cells to improve patients' symptoms," says Viviane Tabar, a neurosurgeon and stem cell biologist at Memorial Sloan Kettering Cancer Center in New York.

Henchcliffe and Tabar joined several other prominent scientists to describe plans to revive brain cell transplants during a session Tuesday at the International Society for Stem Cell Research meeting in Boston.

Their upbeat message marks a dramatic turnaround for the approach.

During the 1980s and 1990s, researchers used cells taken directly from the brains of aborted fetuses to treat hundreds of Parkinson's patients. The goal was to halt the disease.

Parkinson's destroys brain cells that make a substance called dopamine. Without enough dopamine, nerve cells can't communicate with muscles, and people can develop tremors, have difficulty walking and other symptoms.

Drugs can temporarily raise dopamine levels, easing symptoms. But their effectiveness tends to wane over time.

So researchers thought a better approach would be to simply replace the cells that produce dopamine. "The rationale is that if those cells are lost, and we know they make dopamine, and we know that dopamine is important for good coordination, good automatic movement, why could we not replace those cells," Henchcliffe says.

For some patients, the transplanted fetal cells produced dramatic improvements. But rigorous studies eventually showed that many other patients were not helped. And some developed an unwelcome side effect: uncontrolled movements.

So in 2003, researchers declared a moratorium on transplants for Parkinson's. "There was a stepping back to re-evaluate what exactly just happened," Henchcliffe says.

That took a while. But it's clear now that over the long term, some patients really were helped by the procedure.

Henchliffe got to examine five people who'd received transplants more than 15 years earlier.

"These were patients with decades of Parkinson's disease, and I thought it was really striking that a subset actually seemed to be doing much better than one would expect," she says.

Meanwhile, researchers never stopped looking for ways to make cell transplants safer and more effective.

The early transplants were pretty crude, Tabar says. One problem was that the cells came directly from the brains of fetuses, she says.

"What you were placing in the patient was just a soup of brain," she says. "It did not have only the dopamine neurons, which exist in the tissue, but also several different types of cells."

Some of those other cells may also have grown in the patients' brains, causing side effects, she says.

To prevent that sort of problem, scientists at Sloan Kettering have spent the past dozen years figuring out how to turn stem cells into pure lines of dopamine cells in the lab.

Unlike the transplanted fetal cells, these cells are an exact replacement for the neurons that produce dopamine in an adult brain, "So you are confident that everything you are putting in the patient's brain will consist of right type of cell," Tabar says.

Another advantage of lab-grown cells is that the supply is unlimited. "Not only can we grow them, in fact we have almost 1,000 doses of these cells already sitting in a freezer," Tabar says.

Tabar, along with her colleague and husband, Lorenz Studer, hope the Food and Drug Administration will give them permission to begin testing those cells in Parkinson's patients in 2018.

Both have a financial stake in a startup that's funding the project.

Meanwhile, several other groups around the globe are also launching transplant studies. Researchers say a handful of patients in Australia have already received cells.

Some scientists are worried that the renewed rush to make transplants work could lead to more disappointments.

But Tabar says the time is right. "On the one hand, you don't want to rush," she says. "On the other hand I think the field is ready for something bold."

More here:
Brain Cell Transplants Are Being Tested Once Again For Parkinson's - NPR

Stem cell research could help the infertile – Shanghai Daily (subscription)

SCIENTISTS at Beijings Tsinghua University are leading the world in inducing in-vitro differentiation of human embryonic stem cells into follicle-like cells. The breakthrough is expected to help the study of premature ovarian failure and improve assisted reproductive technology.

The achievement of the research team led by Professor Kehkooi Kee was published in the latest issue of academic journal Nature Communications.

The research showed the differentiation of human embryonic stem cells into follicle-like cells can be achieved under the combined action of two RNA-binding proteins specifically expressed in germ cells, DAZL and BOULE, and growth factors GDF9 and BMP15.

Kee, a Malaysian Chinese scientist, said that unlike somatic cells, germ cells can transmit the genetic chromosomes of the father and mother to the next generation. In the genetic process, germ cells undergo unique meiosis and genetic recombination.

How do the germ cells regulate this process? How do they keep the balance between passing the genes to the next generation and creating a diverse genome? That is the most interesting question for me in this field of study, said Kee.

However, scientists must overcome difficulties. Although they can obtain some human germ cell samples by patient agreement, the sample size is far from enough for molecular experiments and cell experiments.

We needed to build an in-vitro platform to study the various mechanisms during the process of human germ cell development. So we chose human embryonic stem cells to differentiate into germ cells, including sperms and eggs, Kee said.

In 2009, he and his colleagues used human embryonic stem cells to create human primordial germ cells and sperm-like cells for the first time.

After successfully culturing human sperm-like cells in-vitro, Kees team tried to culture follicle-like cells. A follicle is composed of an oocyte and many granulosa cells around it. At first we thought inducing the formation of granulosa cells would be a challenge.

But it was found that growth factors GDF9 and BMP15 could promote the development of follicles.

We have compared the in-vitro cultured cells with in-vivo cells, and found they have many similar characteristics. But we can only call the in-vitro cells follicle-like, because we cant prove they are exactly the same until we conduct functional experiments, Kee said. We hope to improve the efficiency of our experiment, and culture more mature antral follicles to test their function.

Helping the infertile is the aim of the research team. Some women cannot have babies because of premature ovarian failure. We might study whether this is caused by gene mutations by conducting in-vitro germ cell experiments, and then develop treatments, Kee said.

The team is also attempting to induce the differentiation of human embryonic stem cells into germ cells on Chinas first cargo spacecraft, Tianzhou-1, to study the effects of the space environment on human reproduction.

Excerpt from:
Stem cell research could help the infertile - Shanghai Daily (subscription)